Press Releases

Amgen and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies.  Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 bill

Mirum Pharmaceuticals, Inc. and GC Pharma today announced that they have entered into an exclusive licensing agreement, pursuant to which GC Pharma has agreed to develop and commercialize maralixibat in South Korea. Maralixibat is an investigational, orally administered medication being evaluated in Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Maralixibat targets the apical sodium dependent bile acid transporter (ASBT) ult

NuProbe Global, a genomics and molecular diagnostics company specialized in ultrasensitive oncology assays, announced research on DNA microsatellites published today in Nucleic Acids Research.  Simultaneously, the company announced the release of the VarTrace® MSI qPCR research use only assay for detection of DNA microsatellite instability (MSI) from tissue or blood specimens. MSI is a genetic condition that is present in roughly 15% of colorectal cancer patients and 30% of

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek®, a

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing pipeline of investigational therapies, it has identified several proprietary drug candidates, including TC220 and TC221. “TLS is the only company developing comprehensive, in-house target drugs as well as a neutron technology system called Alphabeam™ to enable the next-generation in biologic

908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced outcomes of its joint innovation partnership with Transcenta, a global biotherapeutics company. Transcenta has implemented 908 Devices’ technologies within its Process and Product Development Center and Manufacturing Facility in Hangzhou, China to facilitate their biopharma analytical workflows across large molecule characterization and formulation proce

Aptamer Group, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics. The collaboration will aim to identify Optimers for use as Optimer-drug conjugates for targeted delivery of diverse payloads to new cellular targets. Achieving targeted delivery of drugs to specific tissues and organs c

A growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners that provide strategic support and comprehensive resources for their development process of new, promising injectable drug products. Vetter, a leading global Contract Development and Manufacturing Organization (CDMO) has further invested in additional capacity to meet this growing global demand. Only one year after the purchase of the clinical manufacturing location in Rankweil, Aust

Ligand Pharmaceuticals Incorporated announced Jazz Pharmaceuticals plc has launched Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458. Rylaze, which was approved by the FDA on June 30, 2021, is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersens

Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021. Major presentations regarding